Table 1. The most commonly reported side effects
Age group
1040 adults 2189 Adults 3349 Adults 2109 Adults
aged 50-59 years Aged 60-69 years Aged 70-79 years 80 years and Older
Side effects in the arm where the vaccine was injected
Pain 495 (47.6 %) 1000 (45.7 %) 1152 (34.4 %) 525 (24.9 %)
Redness 179 (17.2 %) 383 (17.5 %) 529 (15.8 %) 220 (10.4 %)
Swelling 125 (12.0 %) 307 (14.0 %) 349 (10.4 %) 147 (7.0 %)
Other side effects
Fever 222 (21.3 %) 342 (15.6 %) 315 (9.4 %) 116 (5.5 %)
Headache 135 (13.0 %) 207 (9.5 %) 164 (4.9 %) 57 (2.7 %)
Muscle pain 97 (9.3 %) 136 (6.2 %) 83 (2.5 %) 35 (1.7 %)
Tiredness 59 (5.7 %) 121 (5.5 %) 128 (3.8 %) 43 (2.0 %)
Note: Some volunteers had more than one side effect
How has this study helped patients and researchers?
The researchers learned more about the safety of the new shingles vaccine. The results from this study
did not raise any health concerns. This additional safety information provides reassurance to people who
receive this vaccine. Also, the people who took part in this study benefit from receiving a shingles vaccine.
Are there plans for further studies?
There are several ongoing and planned studies of the new shingles vaccine in different groups of adults.
Where can I find more information about this study?
The detailed title for this research study is:
A phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate
the safety of GSK Biologicals' Herpes ZOSTER subunit (HZ/su) vaccine when administered intramuscularly
on a two-dose schedule to subjects who previously received placebo in ZOSTER-006 and ZOSTER-022
studies.
Clinical studies have unique study numbers. These are the unique study numbers associated with this
study
Organization Website Study Number
European Medicines Agency www.clinicaltrialsregister.eu 2015-000965-30
United States National Institutes www.clinicaltrials.gov NCT02690207
of Health (NIH)